Klaus Lindpaintner, MD, MPH, FACP is Chief Scientific Officer and Vice President at Thermo Fisher Scientific, the world’s leading provider of innovation-driven analytical instruments, reagents, and services to the scientific community, industry, and civil society. Previously, he held senior positions at F. Hoffman-La Roche, where he spearheaded the company’s efforts in personalized health care and was responsible for the respective activities in translational research across the value chain from early discovery to late-stage clinical trials; at SDIX, a specialty antibody-focused biotechnology company, as VP of R&D and CSO; and on the faculty of Harvard Medical School. In addition, he is the principal at bio-banks consulting llc. Klaus has co-authored more than 250 scientific papers, and currently holds honorary and adjunct professorships at several academic institutions. He continues to serve on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities and non-governmental organizations on issues related to the successful implementation and leverage of novel technologies in applied research, and, as a matter of personal interest, the ethical and societal impact of these technologies, and the implications that this may have for deploying them responsibly. Klaus graduated from Innsbruck University Medical School with a degree in medicine and from Harvard University with a degree in public health. He pursued post-graduate training and specialization in internal medicine, cardiology, and genetics in the US and Germany and holds board certification in these specialties. He pursued clinical practice in these areas and academic research in molecular genetics and genetic epidemiology while an Associate Professor of Medicine at Harvard Medical School. He is married to Lyn, an internist-geriatrician, and has two daughters who are pursuing undergraduate and graduate training. In his leisure time he likes to pursue high-altitude mountaineering, photography, and travel.